Luca Gianni

List of Publications by Year
in descending order

154 papers	36,674 citations	14614 66 h-index	8835 145 g-index
161 all docs	161 docs citations	161 times ranked	31647 citing authors

#	Article	IF	Citations
1	Treatment landscape of triple-negative breast cancer â€" expanded options, evolving needs. Nature Reviews Clinical Oncology, 2022, 19, 91-113.	12.5	414
2	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2â€positive and ERâ€positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular Oncology, 2022, 16, 2355-2366.	2.1	3
3	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. Npj Breast Cancer, 2022, 8, 1.	2.3	17
4	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€"Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology, 2022, 40, 438-448.	0.8	35
5	Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptorâ€" and ErbB2-positive Breast Cancer. Clinical Cancer Research, 2022, 28, 2167-2179.	3.2	8
6	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori, 2022, 108, 196-203.	0.6	6
7	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancerâ€"phase 3 ASCENT study subanalysis. Npj Breast Cancer, 2022, 8, .	2.3	25
8	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease, 2021, 53, 117-121.	0.4	1
9	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
10	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€ˆ864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	5.1	147
11	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5096-5108.	3.2	12
12	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treatment Reviews, 2021, 99, 102229.	3.4	15
13	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Oncology, 2021, 11, 827625.	1.3	7
14	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2020, 85, 641-650.	1.1	8
15	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Research, 2019, 39, 797-802.	0.5	0
16	Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.. Journal of Clinical Oncology, 2019, 37, 515-515.	0.8	10
17	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. Journal of Clinical Oncology, 2019, 37, 527-527.	0.8	4
18	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	5.1	183

#	Article	IF	Citations
19	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open, 2018, 3, e000303.	2.0	12
20	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€“3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 413-423.	3.7	180
21	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. British Journal of Cancer, 2018, 118, 679-697.	2.9	17
22	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncology, The, 2018, 19, 249-256.	5.1	130
23	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancerâ€”The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial. JAMA Oncology, 2018, 4, 302.	3.4	115
24	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, The, 2018, 19, 27-39.	5.1	717
25	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
26	Is there room for another HER2-targeting drug?. Lancet Oncology, The, 2018, 19, 847-849.	5.1	3
27	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 691-697.	3.7	50
28	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin inÂlocally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer, 2018, 102, 95-102.	1.3	50
29	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. Journal of Clinical Oncology, 2018, 36, 1059-1059.	0.8	38
30	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. Journal of Clinical Oncology, 2018, 36, e13012-e13012.	0.8	0
31	The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS2596-TPS2596.	0.8	0
32	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, The, 2017, 389, 1195-1205.	6.3	770
33	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Research, 2017, 19, 16.	2.2	83
34	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 2017, 77, 3280-3292.	0.4	76
35	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 732-742.	5.1	447
36	HER2-positive breast cancer. Lancet, The, 2017, 389, 2415-2429.	6.3	655

#	Article	IF	Citations
37	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115.	1.3	25
38	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 2016, 13, 674-690.	12.5	1,938
39	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncology, The, 2016, 17, 791-800.	5.1	623
40	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. British Journal of Cancer, 2016, 115, 290-296.	2.9	29
41	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Breast Cancer Research and Treatment, 2016, 155, 127-132.	1.1	7
42	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2016, 15, 702-710.	1.9	103
43	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clinical Cancer Research, 2016, 22, 337-345.	3.2	58
44	Introduction and background biology. , 2016, , 1-13.		0
45	Pathological complete response in breast cancer â€“ Authors' reply. Lancet, The, 2015, 385, 114-115.	6.3	2
46	Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. Journal of Clinical Oncology, 2015, 33, 2158-2165.	0.8	27
47	Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Early-Stage Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1136-1142.	0.8	67
48	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1003-1003.	0.8	101
49	Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).. Journal of Clinical Oncology, 2015, 33, 505-505.	0.8	19
50	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. Journal of Clinical Oncology, 2015, 33, 512-512.	0.8	8
51	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. PLoS ONE, 2015, 10, e0123194.	1.1	11
52	Strategies for clinical development of monoclonal antibodies beyond first-in-man trials: Tested doses and rationale for dose selection.. Journal of Clinical Oncology, 2015, 33, 3040-3040.	0.8	0
53	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 433.	0.6	12
54	Hallmarks of triple negative breast cancer emerging at last?. Cell Research, 2014, 24, 904-905.	5.7	45

#	Article	IF	Citations
55	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Research, 2014, 16, R50.	2.2	49
56	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	6.3	3,224
57	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 580-591.	5.1	434
58	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncology, The, 2014, 15, 640-647.	5.1	406
59	The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncology, The, 2014, 15, e58-e68.	5.1	244
60	BOLERO-3 results: pharmacological activity or pharmacokinetic effect? â€“ Authors' reply. Lancet Oncology, The, 2014, 15, e304-e305.	5.1	1
61	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 1188-1196.	1.2	20
62	Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive, Locally Advanced, or Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1437-1444.	0.8	72
63	Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research, 2014, 20, 511-521.	3.2	191
64	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). Journal of Clinical Oncology, 2014, 32, 2159-2165.	0.8	207
65	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. PLoS ONE, 2014, 9, e86511.	1.1	10
66	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 530-530.	0.8	0
67	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, The, 2013, 382, 1021-1028.	6.3	447
68	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 1719-1725.	0.8	247
69	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 1236-1243.	1.2	15
70	HER2-Directed T-Cell Receptorâ€“Mimicking Antibody: A â€œMe Tooâ€•or an Example of Novel Antitumor Aggressive Mimicry?. Journal of the National Cancer Institute, 2013, 105, 161-163.	3.0	1
71	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology, 2013, 31, 1954-1960.	0.8	39
72	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Research, 2013, 15, R86.	2.2	44

#	Article	IF	Citations
73	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.. Journal of Clinical Oncology, 2013, 31, 503-503.	0.8	10
74	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. Journal of Clinical Oncology, 2013, 31, 505-505.	0.8	34
75	Introduction and Background Biology. , 2013, , 1-12.		0
76	Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).. Journal of Clinical Oncology, 2013, 31, 537-537.	0.8	0
77	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. Journal of Clinical Oncology, 2013, 31, 1014-1014.	0.8	2
78	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 25-32.	5.1	1,879
79	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1594-1600.	0.8	221
80	Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology, 2012, 9, 16-32.	12.5	735
81	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 367, 1783-1791.	13.9	3,020
82	A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2012, 12, 167-174.	1.1	5
83	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast, 2012, 21, 507-513.	0.9	36
84	Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.. Journal of Clinical Oncology, 2012, 30, 532-532.	0.8	5
85	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	0.8	29
86	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	0.8	34
87	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncology, The, 2011, 12, 236-244.	5.1	575
88	Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 2011, 125, 447-455.	1.1	142
89	Surrogate Markers for Targeted Therapy-Based Treatment Activity and Efficacy. Journal of the National Cancer Institute Monographs, 2011, 2011, 91-94.	0.9	2
90	Triple-Negative Breast Cancer: An Unmet Medical Need. Oncologist, 2011, 16, 1-11.	1.9	636

#	Article	IF	Citations
91	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	0.9	61
92	Pertuzumab â€“ a HER-2 Dimerisation Inhibitor â€“ for the Treatment of Breast and Other Cancers. , 2011, , 73-90.		0
93	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research, 2010, 70, 8852-8862.	0.4	58
94	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1131-1137.	0.8	214
95	Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine. Journal of Clinical Oncology, 2010, 28, 4554-4561.	0.8	47
96	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. Journal of Clinical Oncology, 2010, 28, 1138-1144.	0.8	593
97	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptorâ€“Positive and â€“Negative Cancers. Journal of Clinical Oncology, 2010, 28, 4316-4323.	0.8	193
98	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, The, 2010, 375, 377-384.	6.3	1,061
99	Triple-negative breast cancer: disease entity or title of convenience?. Nature Reviews Clinical Oncology, 2010, 7, 683-692.	12.5	708
100	Role of Anthracyclines in the Treatment of Early Breast Cancer. Journal of Clinical Oncology, 2009, 27, 4798-4808.	0.8	82
101	Reply to S.M. Ali et al. Journal of Clinical Oncology, 2009, 27, e274-e275.	0.8	1
102	Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2474-2481.	0.8	194
103	Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nature Clinical Practice Oncology, 2009, 6, 93-104.	4.3	75
104	Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1685-1693.	0.8	100
105	Anthracyclines and Early Breast Cancer: The End of an Era?. Journal of Clinical Oncology, 2009, 27, 1155-1157.	0.8	15
106	Never use anthracyclines with trastuzumab: it is time to reconsider the taboo. Breast Cancer Research and Treatment, 2009, 117, 599-601.	1.1	4
107	Longâ€term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germâ€cell tumours. BJU International, 2009, 104, 340-346.	1.3	34
108	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-624.	0.7	102

#	Article	IF	Citations
109	State of the art of adjuvant therapy. European Journal of Cancer, Supplement, 2008, 6, 27-30.	2.2	0
110	The â€œOtherâ€•Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs. Journal of Clinical Oncology, 2008, 26, 1778-1780.	0.8	20
111	Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. Journal of Clinical Oncology, 2008, 26, 814-819.	0.8	352
112	Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. , 2008, , .		5
113	Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 790-800.	1.3	35
114	Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs. Journal of Clinical Oncology, 2007, 25, 3389-3391.	0.8	25
115	Anthracycline Cardiotoxicity. Topics in Current Chemistry, 2007, 283, 21-44.	4.0	26
116	Targeting TRAIL Agonistic Receptors for Cancer Therapy. Clinical Cancer Research, 2007, 13, 2313-2317.	3.2	67
117	Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 2007, 7, 67-71.	1.1	107
118	Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study. Clinical Breast Cancer, 2006, 7, 321-325.	1.1	5
119	Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. European Journal of Cancer, 2006, 42, 171-178.	1.3	39
120	Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart. Journal of Biological Chemistry, 2006, 281, 10990-11001.	1.6	88
121	Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 424-433.	1.3	63
122	The cost of life: should it matter to doctors?. Annals of Oncology, 2006, 17, 357-358.	0.6	3
123	Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7265-7277.	0.8	531
124	Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy. Clinical Cancer Research, 2005, 11, 8715-8721.	3.2	146
125	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. Journal of Clinical Oncology, 2005, 23, 1867-1874.	0.8	163
126	30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ: British Medical Journal, 2005, 330, 217.	2.4	224

#	Article	IF	Citations
127	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. European Journal of Cancer, 2005, 41, 1746-1750.	1.3	138
128	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353, 1659-1672.	13.9	4,601
129	Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nature Clinical Practice Oncology, 2004, 1, 44-50.	4.3	22
130	Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer. Journal of Clinical Oncology, 2004, 22, 1614-1620.	0.8	106
131	Future options with trastuzumab for primary systemic and adjuvant therapy. Seminars in Oncology, 2004, 31, 51-57.	0.8	45
132	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (â€˜Iressaâ€™) is independent of EGFR expression level. Journal of Cellular Physiology, 2004, 198, 259-268.	2.0	108
133	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 2004, 56, 185-229.	7.1	3,060
134	Cardiotoxic effects of anthracyclineâ€“taxane combinations. Expert Opinion on Drug Safety, 2003, 2, 59-71.	1.0	21
135	International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. Journal of Clinical Oncology, 2003, 21, 2600-2608.	0.8	322
136	Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clinical Cancer Research, 2003, 9, 5944-51.	3.2	42
137	The Future of Targeted Therapy: Combining Novel Agents. Oncology, 2002, 63, 47-56.	0.9	22
138	Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Nodeâ€“Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables. Journal of Clinical Oncology, 2001, 19, 329-335.	0.8	147
139	Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer. Journal of Clinical Oncology, 2001, 19, 2222-2231.	0.8	38
140	Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation. Journal of Clinical Oncology, 2001, 19, 37-43.	0.8	170
141	Mechanism-Based Pharmacokinetic Model for Paclitaxel. Journal of Clinical Oncology, 2001, 19, 4065-4073.	0.8	133
142	Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. Investigational New Drugs, 2001, 19, 179-196.	1.2	26
143	Adjuvant and neoadjuvant treatment of breast cancer. Seminars in Oncology, 2001, 28, 13-29.	0.8	22
144	Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anti-Cancer Drugs, 2000, 11, 331-337.	0.7	52

#	Article	IF	Citations
145	New active drugs in the treatment of lymphomas. Current Opinion in Oncology, 1994, 6, 480-488.	1.1	3
146	Learning from Cl-941 about pharmacokinetically guided dose escalation. European Journal of Cancer, 1992, 28, 1302-1304.	1.3	3
147	Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Annals of Oncology, 1991, 2, 9-16.	0.6	68
148	Cisplatin and Cyclophosphamide in Advanced Ovarian Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1990, 13, 199-203.	0.6	3
149	Monoclonal antibodies against doxorubicin. International Journal of Cancer, 1988, 42, 798-802.	2.3	15
150	Four-drug sequential regimen in advanced breast cancer. Breast Cancer Research and Treatment, 1987, 10, 151-157.	1.1	3
151	Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. Biochimica Et Biophysica Acta - General Subjects, 1986, 884, 326-336.	1.1	58
152	Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Letters, 1984, 172, 226-230.	1.3	136
153	Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry, 1984, 23, 928-936.	1.2	168
154	Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry, 1982, 21, 1707-1713.	1.2	232